Health-related quality of life questionnaires in lung cancer trials: A systematic literature review

被引：48
作者：
Damm K. [1 ]
Roeske N. [1 ]
Jacob C. [2 ]
机构：
[1] Center for Health Economics Research Hannover (CHERH), Leibniz University Hannover, Hannover
[2] Herescon GmbH, Hannover
来源：
Health Economics Review | / 3卷 / 1期
关键词：
Health economics; Health-related quality of life; Lung cancer; Questionnaires; Utility measurement;
D O I：
10.1186/2191-1991-3-15
中图分类号：
学科分类号：
摘要：
Background: Lung cancer is one of the leading causes of cancer deaths. Treatment goals are the relief of symptoms and the increase of overall survival. With the rising number of treatment alternatives, the need for comparable assessments of health-related quality of life (HRQoL) parameters grows. The aim of this paper was to identify and describe measurement instruments applied in lung cancer patients under drug therapy. Methods: We conducted a systematic literature review at the beginning of 2011 using the electronic database Pubmed. Results: A total of 43 studies were included in the review. About 17 different measurement instruments were identified, including 5 generic, 5 cancer-specific, 4 lung cancer-specific and 3 symptom-specific questionnaires. In 29 studies at least 2 instruments were used. In most cases these were cancer and lung cancer-specific ones. The most frequently used instruments are the EORTC QLQ-C30 and its lung cancer modules LC13 or LC17. Only 5 studies combined (lung) cancer-specific questionnaires with generic instruments. Conclusions: The EORTC-C30 and EORTC-LC13 are the most frequently used health-related quality of life measurement instruments in pharmacological lung cancer trials. © 2013 Damm et al.; licensee Springer.
引用
收藏
页码：1 / 10
相关论文
共 55 条
[1]  
(2010) Gesellschaft Der Epidemiologischen Krebsregister In Deutschland E. V: Krebs In Deutschland 2005/2006, , Robert Koch Institut, Berlin: Häufigkeiten und Trends
[2]  
Reck, M., Quality of life as an endpoint of clinical trials (2009) Lung Cancer, 64 (SUPPL. 1), pp. 22-23
[3]  
Liu, J., Mittendorf, T., von der Schulenburg, J.M., A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia (2010) Cancer Invest, 28, pp. 312-322
[4]  
Camps, C., del Pozo, N., Blasco, A., Blasco, P., Sirera, R., Importance of quality of life in patients with Non-small-cell lung cancer (2009) Clin Lung Cancer, 10, pp. 83-90
[5]  
Schöffski, O., Lebensqualität als Ergebnisparameter in gesundheitsökonomischen Studien (2007) Gesundheitsökonomische Evaluationen, pp. 321-334. , Edited by Schöffski O, Von der Schulenburg JM. Berlin: Heidelberg: Springer
[6]  
Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement (2009) BMJ, 339, pp. 332-336
[7]  
Agteresch, H.J., Rietveld, T., Kerkhofs, L.G., van den Berg, J.W., Wilson, J.H., Dagnelie, P.C., Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: A randomized clinical trial (2002) J Clin Oncol, 20, pp. 371-378
[8]  
Baka, S., Ashcroft, L., Anderson, H., Lind, M., Burt, P., Stout, R., Dowd, I., Thatcher, N., Randomized phase II study of Two gemcitabine schedules for patients with impaired performance status (karnofsky performance status 70) and advanced Non-small-cell lung cancer (2005) J Clin Oncol, 23, pp. 2136-2144
[9]  
Belani, C.P., Pereira, J.R., von Pawel, J., Pluzanska, A., Gorbounova, V., Kaukel, E., Mattson, K.V., Fossella, F., Effect of chemotherapy for advanced Non-small cell lung cancer on Patients' quality of life - a randomized controlled trial (2006) Lung Cancer, 53, pp. 231-239. , TAX 326 study group
[10]  
Bezjak, A., Lee, C.W., Ding, K., Brundage, M., Winton, T., Graham, B., Whitehead, M., Shepherd, F.A., Quality-of-life outcomes for adjuvant chemotherapy in early-stage Non-small-cell lung cancer: Results from a randomized trial, JBR.10 (2008) J Clin Oncol, 26, pp. 5052-5059
123456